金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2022-11-18

The CTA of Anti-PD-1 mAb Serplulimab for MRCT Phase 3 Studies on First-Line LS-SCLC Patients Approved in EU
2022-11-11

The IND Application of Phase 1b/2 Clinical Trial of BARF V600E Inhibitor HLX208 in Combination with HANSIZHUANG for the Treatment of BARF V600 Mutation-Positive Solid Tumours was Approved by the NMPA
2022-11-09

Henlius' Innovative Asymmetric Bispecific Antibody CLD Platform Published in Biochemical Engineering Journal
2022-11-04

Henlius Wins Generics Bulletin ‘Business Development of the Year’ Award
2022-11-01

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC
2022-10-28

Henlius Pertuzumab Biosimilar HLX11 Received Clinical Trial Approval in EU for the Phase 3 MRCT
2022-10-28

The Phase 2 IND Application of Henlius’ Novel Anti-HER2 mAb HLX22 Combined with Anti-PD-1 mAb HANSIZHUANG and HANQUYOU for the Treatment of HER2+ Gastric Cancer Approved by NMPA
2022-10-27

Phase 2 Study of the PD-1 Inhibitor Serplulimab in Patients with MSI-H Solid Tumours Published in British Journal of Cancer
2022-10-25

Henlius Anti-PD-1 mAb Serplulimab Combined with Chemotherapy and Concurrent Radiotherapy MRCT Phase 3 Study on First-Line LS-SCLC Patients Received Clinical Trial Approved in Australia